REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)
Status:
Completed
Trial end date:
2017-04-18
Target enrollment:
Participant gender:
Summary
The trial is conducted in the United Kingdom (UK), Australia, Canada, Denmark and the
Netherlands. The aim is to test whether 3 years treatment with metformin added to titrated
insulin therapy (towards target HbA1c 7.0%/53 mmol/mol) reduces atherosclerosis, as measured
by progression of carotid intima-media thickness (cIMT), in adults with confirmed type 1
diabetes aged 40 years and over at increased risk for cardiovascular disease.
Phase:
Phase 3
Details
Lead Sponsor:
University of Glasgow
Collaborators:
Imperial College London Itamar-Medical, Israel Juvenile Diabetes Research Foundation Maastricht University Medical Center Merck Serono S.A., Geneva NHS Greater Glasgow and Clyde Steno Diabetes Center Steno Diabetes Center Copenhagen University of Dundee University of Melbourne University of Western Ontario, Canada University of Wisconsin, Madison